1.Elsegeiny W, Marr KA, Williamson PR: Immunology of Cryptococcal Infections: Developing a Rational Approach to Patient Therapy. Front Immunol 2018, 9:651.
2.Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, Denning DW, Loyse A, Boulware DR: Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis 2017, 17(8):873–881.
3.Pyrgos V, Seitz AE, Steiner CA, Prevots DR, Williamson PR: Epidemiology of cryptococcal meningitis in the US: 1997–2009. PLoS One 2013, 8(2):e56269.
4.Kiertiburanakul S, Wirojtananugoon S, Pracharktam R, Sungkanuparph S: Cryptococcosis in human immunodeficiency virus-negative patients. Int J Infect Dis 2006, 10(1):72–78.
5.Brizendine KD, Baddley JW, Pappas PG: Predictors of mortality and differences in clinical features among patients with Cryptococcosis according to immune status. PLoS One 2013, 8(3):e60431.
6.Alanio A, Vernel-Pauillac F, Sturny-Leclere A, Dromer F: Cryptococcus neoformans host adaptation: toward biological evidence of dormancy. MBio 2015, 6(2).
7.Jarvis JN, Wainwright H, Harrison TS, Rebe K, Meintjes G: Pulmonary cryptococcosis misdiagnosed as smear-negative pulmonary tuberculosis with fatal consequences. Int J Infect Dis 2010, 14 Suppl 3:e310–312.
8.George IA, Spec A, Powderly WG, Santos CAQ: Comparative Epidemiology and Outcomes of Human Immunodeficiency virus (HIV), Non-HIV Non-transplant, and Solid Organ Transplant Associated Cryptococcosis: A Population-Based Study. Clin Infect Dis 2018, 66(4):608–611.
9.Guo LY, Liu LL, Liu Y, Chen TM, Li SY, Yang YH, Liu G: Characteristics and outcomes of cryptococcal meningitis in HIV seronegative children in Beijing, China, 2002–2013. BMC Infect Dis 2016, 16(1):635.
10.Hung CW, Lin WC, Chang WN, Su TM, Kung CT, Tsai NW, Wang HC, Huang CC, Cheng BC, Su YJ et al: Risk factors and outcomes of cerebrospinal fluid overdrainage in HIV-negative patients with cryptococcal meningitis after the ventriculoperitoneal shunting procedure. J Microbiol Immunol Infect 2018, 51(4):545–551.
11.Li M, Chen Z, Xu L, Gan Z, Peng F, Liu J: A Comparison of the Clinical Characteristics and Outcomes of Cryptococcal Meningitis in HIV-negative Individuals With and Without Immunosuppression. Neurologist 2019, 24(1):1–5.
12.Naik KR, Saroja AO, Doshi DK: Hospital-based Retrospective Study of Cryptococcal Meningitis in a Large Cohort from India. Ann Indian Acad Neurol 2017, 20(3):225–228.
13.Qu J, Zhou T, Zhong C, Deng R, Lu X: Comparison of clinical features and prognostic factors in HIV-negative adults with cryptococcal meningitis and tuberculous meningitis: a retrospective study. BMC Infect Dis 2017, 17(1):51.
14.Zhong YH, Tan F, Li M, Liu J, Wang X, Yuan Y, Zhong XF, Peng FH: Comparisons of presentations and outcomes of cryptococcal meningitis between patients with and without hepatitis B virus infection. Int J Infect Dis 2014, 20:31–36.
15.Tsai WC, Lien CY, Lee JJ, Hsiao WC, Huang CR, Tsai NW, Chang CC, Lu CH, Chang WN: The clinical characteristics and therapeutic outcomes of cryptococcal meningitis in elderly patients: a hospital-based study. BMC Geriatr 2019, 19(1):91.
16.Lu CH, Chang WN, Chang HW, Chuang YC: The prognostic factors of cryptococcal meningitis in HIV-negative patients. J Hosp Infect 1999, 42(4):313–320.
17.Williamson PR, Jarvis JN, Panackal AA, Fisher MC, Molloy SF, Loyse A, Harrison TS: Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. Nat Rev Neurol 2017, 13(1):13–24.
18.Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster DJ, Henderson H, Kauffman CA, Haas DW, Saccente M et al: Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001, 33(5):690–699.
19.Smith KD, Achan B, Hullsiek KH, McDonald TR, Okagaki LH, Alhadab AA, Akampurira A, Rhein JR, Meya DB, Boulware DR et al: Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda. Antimicrob Agents Chemother 2015, 59(12):7197–7204.
20.Bongomin F, Oladele RO, Gago S, Moore CB, Richardson MD: A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species. Mycoses 2018, 61(5):290–297.
21.Henao-Martinez AF, Chastain DB, Franco-Paredes C: Treatment of cryptococcosis in non-HIV immunocompromised patients. Curr Opin Infect Dis 2018, 31(4):278–285.
22.Vu K, Garcia JA, Gelli A: Cryptococcal Meningitis and Anti-virulence Therapeutic Strategies. Front Microbiol 2019, 10:353.
23.Phillips P, Galanis E, MacDougall L, Chong MY, Balshaw R, Cook VJ, Bowie W, Steiner T, Hoang L, Morshed M et al: Longitudinal clinical findings and outcome among patients with Cryptococcus gattii infection in British Columbia. Clin Infect Dis 2015, 60(9):1368–1376.
24.Gaskell KM, Rothe C, Gnanadurai R, Goodson P, Jassi C, Heyderman RS, Allain TJ, Harrison TS, Lalloo DG, Sloan DJ et al: A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in Blantyre, Malawi. PLoS One 2014, 9(11):e110285.
25.Chen SC, Slavin MA, Heath CH, Playford EG, Byth K, Marriott D, Kidd SE, Bak N, Currie B, Hajkowicz K et al: Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin Infect Dis 2012, 55(6):789–798.